Axsome Therapeutics (AXSM) EBT Margin (2022 - 2025)
Historic EBT Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 27.62%.
- Axsome Therapeutics' EBT Margin rose 340400.0% to 27.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.05%, marking a year-over-year increase of 509200.0%. This contributed to the annual value of 74.45% for FY2024, which is 136100.0% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' EBT Margin is 27.62%, which was up 340400.0% from 32.61% recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' EBT Margin registered a high of 9.13% during Q1 2023, and its lowest value of 469.82% during Q2 2022.
- Its 4-year average for EBT Margin is 128.9%, with a median of 91.09% in 2024.
- In the last 5 years, Axsome Therapeutics' EBT Margin surged by 3246600bps in 2023 and then tumbled by -820100bps in 2024.
- Axsome Therapeutics' EBT Margin (Quarter) stood at 251.29% in 2022, then soared by 45bps to 138.37% in 2023, then soared by 54bps to 63.0% in 2024, then soared by 56bps to 27.62% in 2025.
- Its last three reported values are 27.62% in Q3 2025, 32.61% for Q2 2025, and 48.91% during Q1 2025.